Document Detail

Pharmacokinetic study of recombinant human factor IX in previously treated patients with hemophilia B in Taiwan.
MedLine Citation:
PMID:  17475604     Owner:  NLM     Status:  MEDLINE    
BACKGROUND/PURPOSE: The pharmacokinetic (PK) study of recombinant human factor IX (rFIX) has been done in patients with hemophilia B in areas other than Taiwan. However, wide patient-related variability in recovery is noted and there is no PK study of rFIX in Taiwanese patients with hemophilia B. The purpose of this study is to evaluate the PKs of the rFIX in Taiwanese patients with hemophilia B. METHODS: A PK study of rFIX was performed in 10 previously treated Taiwanese patients with hemophilia B. Nine of them had severe hemophilia B and the other one had moderately severe hemophilia B. The mean age of our patients was 24.7 +/- 8.6 years (mean +/- SD) with a range of 15.5-47.0 years. RESULTS: The infusion of 75 IU/kg of rFIX in our patients resulted in a mean FIX activity increase of 1.08 +/- 0.27 IU/dL per IU/kg with a range of 0.3-1.49 IU/dL per IU/kg, and a mean in vivo recovery of 44.0 +/- 9.5% with a range of 31.4-60.4%. The mean elimination half-life was 24.4 +/- 6.4 hours with a range of 14.1-35.3 hours. The mean values of area under the curve, total body clearance, volume of distribution at steady state were 1363 +/- 166 IU x hour/dL, 4.84 +/- 1.03 mL/hour/kg, and 144.3 +/- 41.8 mL/kg, respectively. In addition, rFIX was well tolerated in our patients. Only two patients experienced mild treatment-related adverse events, including fever and feeling sleepy, respectively. Both of them resolved spontaneously without any sequences, and there was no thrombosis formation or inhibitor development in the following 6 months after rFIX infusion. CONCLUSION: The results of PK study of rFIX in our previously treated Taiwanese patients with hemophilia B are comparable to the reported results from other related studies conducted in different geographical areas.
Hsiu-Hao Chang; Yung-Li Yang; Mei-Hua Hung; Woei Tsay; Ming-Ching Shen
Related Documents :
2448994 - Production of interleukin-2 and interleukin-2 inhibitor in patients with palmoplantar p...
11347834 - Hypofibrinolysis, thrombophilia, osteonecrosis.
7893924 - Coagulation factors and markers of activation of coagulation in homocystinuria (hocy): ...
171794 - Disseminated intravascular coagulation: experience in a major cancer center.
23403884 - Predictive value of high-sensitivity troponin i and d-dimer assays for adverse outcome ...
20709654 - Serum c-telopeptide levels predict the incidence of skeletal-related events in cancer p...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of the Formosan Medical Association = Taiwan yi zhi     Volume:  106     ISSN:  0929-6646     ISO Abbreviation:  J. Formos. Med. Assoc.     Publication Date:  2007 Apr 
Date Detail:
Created Date:  2007-05-03     Completed Date:  2007-07-19     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9214933     Medline TA:  J Formos Med Assoc     Country:  China (Republic : 1949- )    
Other Details:
Languages:  eng     Pagination:  281-7     Citation Subset:  IM    
Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Area Under Curve
Factor IX / pharmacokinetics*
Hemophilia B / drug therapy*
Middle Aged
Recombinant Proteins / pharmacokinetics*
Reg. No./Substance:
0/Recombinant Proteins; 9001-28-9/Factor IX

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Endothelin-1 activates MAPKs and modulates cell cycle proteins in OKP cells.
Next Document:  Gene expression profiles in living donors immediately after partial hepatectomy - the initial respon...